Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Czaykowski
Piotr M
PM
Department of Internal Medicine, University of Manitoba, Winnipeg. Piotr.Czaykowski@cancercare.mb.ca
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002272:Carcinoembryonic Antigen / Q000097:blood; D002277:Carcinoma / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D011799:Quinazolines / Q000008:administration & dosage; D012004:Rectal Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D013876:Thiophenes / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002272:Carcinoembryonic Antigen; D011799:Quinazolines; D013876:Thiophenes; D000068258:Bevacizumab; D000077146:Irinotecan; C068874:raltitrexed; D005472:Fluorouracil; D002166:Camptothecin